Sitagliptin reduces transforming growth factor-β1 and platelet derived growth factor-BB in regulation of UAER in type 2 diabetic nephropathy stage III patients

Biomedical Research (India)

Volumn 28, Issue 6, 2017, Pages 2571-2577

  Yang, Fan ^a   Yu, Tingting ^b   Li, Ke ^c   Jiang, Xiaolan ^a   Li, Jian ^a   Wang, Jia ^a  

^a SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Platelet derived growth factor BB; Sitagliptin; Transforming growth factor 1; Urinary albumin excretion rate

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLATELET DERIVED GROWTH FACTOR BB; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RELEASE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RENAL SYSTEM PARAMETERS; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN EXCRETION RATE;

EID: 85017182207     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zhuo L, Zou G, Li W, Lu J, Ren W. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus. Eur J Med Res 2013; 18: 23432977.
2. Tomino Y, Cooper ME, Kurtz TW, Shimizu Y. Experimental models of type-2 diabetic nephropathy. Exp Diabetes Res 2012.
3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. See comment in PubMed Commons below Kidney Int 2006; 69: 213-217.
6. Ayo SH, Radnik RA, Garoni JA, Glass W 2nd, Kreisberg J. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990; 136: 1339.
7. Ellis D, Forrest KY, Erbey J, Orchard TJ. Urinary measurement of transforming growth factor-ß and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998; 44: 950-956.
8. Castro NE, Kato M, Park JT, Natarajan R. Transforming growth factor ß1 (TGF-ß1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J Biol Chem 2014; 289: 29001-29013.
9. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dialysis Transplant 2003; 18: 1392-1396.
10. Wang QY, Guan QH, Chen FQ. The changes of platelet-derived growth factor-BB (PDGF-BB) in T2DM and its clinical significance for early diagnosis of diabetic nephropathy. Diabetes Res Clin Practice 2009; 85: 166-170.
11. Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res 2015; 2015: 806979.
12. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-151.
13. Marques CIR. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the kidney in a T2DM animal model–Focus on endoplasmic reticulum stress. 2013.
14. Gonçalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro C, Reis F, Ambrósio A, Fernandes R. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood–retinal barrier in a type 2 diabetes animal model. Diabetes Obesity Metabol 2012; 14: 454-463.
15. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. See comment in PubMed Commons below Endocr J 2011; 58: 69-73.
16. Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, Kurose T, Seino Y. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obesity Metabol 2015; 17: 430-434.
17. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Invest 2014; 5: 313-319.
18. Mega C, Vala H, Rodrigues-Santos P, Oliveira J, Teixeira F, Fernandes R, Reis F, de Lemos ET. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat-focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetol Metabol Syndrome 2014; 6: 1.
19. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242.
20. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-197.
21. Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI. Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011; 60: 1271-1277.
22. Dai Y, Palade P, Wang X, Mercanti F, Ding Z, Dai D, Mehta JL. High fat diet causes renal fibrosis in LDLr-null mice through MAPK-NF-?B pathway mediated by Ox-LDL. J Cardiovascular Pharmacol 2014; 63: 158-166.
23. Gao X, Wu G, Gu X, Fu L, Mei C. Kruppel-like factor 15 modulates renal interstitial fibrosis by ERK/MAPK and JNK/MAPK pathways regulation. Kidney Blood Pressure Res 2013; 37: 631-640.
24. Hills CE, Squires PE. TGF-ß1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31: 68-74.
25. Marques C, Mega C, Gonçalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, Fontes-Ribeiro C, Reis F, Fernandes R. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflammation 2014.
26. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochemical Biophysical Res Communications 2014; 443: 828-833.
27. Li J, Guan M, Li C, Lyv F, Zeng Y, Zheng Z, Wang C, Xue Y. The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout mice. Int J Mol Sci 2014; 15: 11416-11434.
28. Mega C, Teixeira de Lemos E, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011.
29. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflammation 2010.
30. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
31. No authors listed. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
32. Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 2012; 159: 303-312.
33. Kawasaki I, Hiura Y, Tamai A, Yoshida Y, Yakusiji Y, Ikuno Y, Okada M, Ueno H, Tanaka N, Yamagami K. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes 2015; 7: 41-46.
34. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996; 335: 1682-1683.